Other News To Note
Wednesday, August 17, 2011
Qiagen NV, of Venlo, the Netherlands, and Pfizer Inc., of New York, inked a partnership to develop a molecular diagnostic test for use with Pfizer's investigational compound, dacomitinib (PF-00299804), an oral inhibitor of HER-1 (EGFR) and other tyrosine kinases that is in clinical development for the treatment of non-small-cell lung cancer.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.